

FRIDAY

18 September

MAIN HALL	HALL 2	HALL 3
08:00 - 09:30 SESSION 22 The hidden problem of analytical interference – how to identify, investigate and prevent? (session by NFKK) Chair: Associate professor <i>Anna Linko-Parvinen</i> (Turku, FI)	08:00 - 09:30 SESSION 23 Mass Spectrometry in Myeloma Chairs: Associate Professor <i>Anders Mønsted Abildgaard</i> (Aarhus DK) and Professor <i>Hans Christian Beck</i> (Odense DK)	08:00 - 09:30 SESSION 24 ctDNA for guiding treatment decisions Chairs: Professor <i>Boe Sørensen</i> (Aarhus DK) and Professor <i>Claus Lindbjerg Andersen</i> (Aarhus DK)
08:00 - 08:30 Immunoglobulins and immunoassays: An introduction to common practical immunoassay challenges. Chief Physician <i>Johan Bjerner</i> Fürst Medical Laboratory, Oslo, Norway	08:00 - 08:20 Minimum Invasion, Maximum Insights - Ultra sensitive blood test for MRD monitoring in Multiple Myeloma Scientific Affairs Officer <i>Ian Ruigrok</i> Sebia, Lisses, France	08:00 - 08:40 NeoCircle: ctDNA monitoring in early breast cancer for evaluating neoadjuvant chemotherapy response and post-operative MRD Associate Professor <i>Lao Saal</i> Division of Oncology, CIRCE Women’s Cancer Research Center, Lund University, Sweden
08:30 - 09:00 Analytical interference in troponin assays Associate Professor <i>Saara Wittfooth</i> Department of Life Technologies, University of Turku, Turku, Finland	08:20 - 08:40 From gel electrophoresis to mass spectrometry: transitioning routine monoclonal protein monitoring to EXENT Dr. <i>Katie Horton</i> Binding Site Group Ltd., Birmingham, UK Measurement of monoclonal proteins is central to the diagnosis and monitoring of monoclonal gammopathies, including multiple myeloma. As deeper treatment responses demand greater analytical sensitivity, MALDI-TOF mass spectrometry has emerged as a powerful alternative to conventional methods. This presentation explores the transition to the EXENT™ system for routine laboratory testing.	08:40 - 09:05 Enhanced ctDNA detection in stage II and III colorectal cancer through whole genome sequencing with single-read error correction Phd student <i>Maria Hønholt Jørgensen</i> Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Early detection of minimal residual disease is essential for optimizing the use of adjuvant chemotherapy. This talk presents a novel ultrasensitive tumor-informed whole-genome sequencing ctDNA assay that can detect, as early as 30 days after surgery, 66% of patients who subsequently develop recurrence. The assay performance supports the potential for ctDNA-guided treatment escalation and de-escalation.
09:00 - 09:30 Suspicion of Thyroid Interference - What Can the Laboratory Do? Chief Physician <i>Per Bjellerup</i> Centre of Clinical Research, Västerås, Sweden	08:40 - 09:05 Validation of the EXENT® System, an automated MALDITOF mass spectrometry system for detection and quantification of Mprotein Chief Physician <i>Marcus Clarin</i> Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden	09:05 - 09:30 ctDNA as a tool for predicting treatment response to EGFR-targeted therapy in lung cancer Postdoctoral researcher, <i>Simone Stensgaard</i> Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus Denmark

The EXENT® System, a fully automated MALDI-TOF mass spectrometry platform, enables sensitive and specific detection, classification, and quantification of M-proteins. It shows strong concordance with reference methods, improved detection of low-level M-proteins, and reduces manual work. The instrument works well for clinical routine samples for detecting M-proteins at low concentrations.

09:05 - 09:30

A non-affinity-dependent high-resolution mass spectrometry method for detecting and typing monoclonal free light immunoglobulin chains

Hospital Chemist *Per Bengtson*
Department of Clinical Chemistry, Halland Hospital, Halland, Sverige

Measuring FLCs is important in the management of B-cell neoplasms. Established immunochemical methods relying on kappa/lambda ratios for monoclonality have limitations. We developed an MS-based method with simple, non-affinity sample preparation that detects isotypes, and semi-quantifies monoclonal monomeric and dimeric light chains, while also identifying post-translational modifications.

MAIN HALL

09:45 - 11:15 SESSION 25

Choosing wisely

Chair: Senior Consultant *Birgitte Sandfeld Paulsen* (Aalborg, DK)

09:45 - 10:15

Hospital-Acquired Anemia

Professor *Henrik Løvendahl Jørgensen*

Department of Clinical Biochemistry, Amager-Hvidovre Hospital, Hvidovre, Denmark

The number of laboratory tests has increased steadily for decades, resulting in increasing cumulative diagnostic blood loss. Diagnostic phlebotomy is an important but often underestimated cause of hospital-acquired anaemia, which is associated with prolonged hospitalisation, increased transfusion requirements and poorer clinical outcomes. Optimising laboratory test patterns may therefore improve both patient safety and resource utilisation.

10:15 - 10:45

Update on Choosing wisely initiative in Medical Biochemistry, Norway

Consultant *Ragnhild V. Nome*

HALL 2

09:45 - 11:15 SESSION 26

Career Paths in Clinical Biochemistry: Opportunities, Challenges, and Future Directions
(session by YLKB)

Chairs: Dr. *Anne Lind Malte* (Aarhus, DK) and Dr. *Sine Voss David* (Copenhagen, DK)

09:45 - 09:50

Welcome and introduction

Dr. *Anne Lind Malte* and Dr. *Sine Voss David*
Departments of Clinical Biochemistry, Aarhus University Hospital, Aarhus Denmark, and Amager-Hvidovre Hospital, Hvidovre, Denmark

9:50-10:15

Clinical biochemistry at the molecular frontier: Connecting genomics, precision medicine, and people across disciplines and institutions

Chief Physician *Ole Halfdan Larsen*

HALL 3

09:45 - 11:15 SESSION 27

Preparedness for War and Crisis in Laboratory Medicine (Session by SFKK)

Chair: Dr. *Henrik von Horn* (Stockholm, SE)

09:45 - 10:30

Laboratory Medicine and Cybersecurity: Preparedness and Resilience

Professor *Giuseppe Lippi*

Dean of Medical Faculty University and Hospital of Verona, Vice-President of Italian Society of Clinical Biochemistry (SIBioC)

10:30 - 11:15

Laboratory Preparedness in Wartime: Lessons from Ukraine

Assistant professor *Nataliia Kozopas*

Department of Clinical Biochemistry, Oslo
University Hospital, Oslo, Norway

The Norwegian interest group is involved in several projects including

- A campaign to reduce unnecessary blood sampling in hospitals initiated from the Norwegian Medical Association
- Choosing wisely recommendations directed at laboratory services
- Information of rational use of blood tests in The National Interpretive Handbook for Medical Biochemistry
- Resource bank for published Choosing wisely quality projects in Medical Biochemistry

10:45 - 11:15

We've Been Saying This for Years: Why Is Changing Test Utilization Still So Hard?

Chief Physician *Else Marie Vestergaard*
Department of Clinical Biochemistry, Horsens
Regional Hospital, Horsens, Denmark

Efforts to reduce low-value laboratory testing are not new. Since the 1990s, laboratories have introduced guidelines, educational initiatives, audit and feedback, and electronic decision support to promote appropriate test utilization. This presentation shows recent experiences from Horsens, highlighting local initiatives, observed effects, and challenges. We discuss why changing test-ordering behavior remains difficult and reflects on the future role of clinical laboratories in a healthcare system facing even more growing demands for diagnostic testing.

Department of Molecular Medicine (MOMA),
Aarhus University Hospital, Aarhus, Denmark

Advances in genomics and precision medicine depend not only on technology, but on creating environments where disciplines, institutions, and professional groups can work together. This talk explores the leadership role in providing such a host environment, enabling shared infrastructure, cross-boundary careers, and synergies between research, diagnostics, and patient care.

10:15 - 10:40

An alternative career path in the pharmaceutical industry – reflections on the transition from clinical chemistry

Medical Director *Elin Rebecka Carlsson*
Global Patient Safety, BioPharma,
AstraZeneca, Sverige

Personal reflections on five years as a Patient Safety Physician at AstraZeneca and the transition from the hospital laboratory mid-Covid, after completed specialist training. What transferred, what did not, which were the real challenges – and what pharma roles suit a clinical chemistry background.

10:40 - 11:05

From resident to chief physician – and why to pursue a career in management

Chief Physician *Rasmus Søgård Hansen*

Department of Clinical Diagnostics, University
Hospital of Southern Denmark, Esbjerg,
Denmark.

In this talk, I will take you through my path and share reflections on difficult choices and opportunities while navigating residency and family life. Career guidance is challenging, but I will try to outline possible career paths after completing specialist training in Clinical Biochemistry

11:05 - 11:15

Wrap-up and open discussion

Department of Clinical Laboratory
Diagnostics, Faculty of Postgraduate
Education, Danylo Halytsky Lviv National
Medical University, Ukraine.

MAIN HALL

11:30 - 12:15 PLENARY LECTURE

The future of healthcare – moving closer to the citizen

Chair: Senior Consultant *Birgitte Sandfeld Paulsen (Aalborg DK)*

Professor *Jakob Kjellberg*, VIVE – The Danish Center for Social Science Research, Denmark



Professor Jakob Kjellberg – a member of the Danish Health Structure Commission (“Sundhedsstrukturkommissionen”) – will share insights from the Commission’s work as a starting point for discussing the future development of Nordic healthcare systems. He will examine the necessary shift from hospital-based care towards community- and primary care-oriented solutions, addressing the magnitude of change required, the implications for clinical practice and laboratory medicine, and the opportunities and challenges in bringing healthcare closer to the citizen.

12:15 - 12:30 CLOSING CEREMONY